



## **AngioDynamics to Hold Fiscal 2007 Second Quarter Financial Results Conference Call on Wednesday, January 3, 2007**

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Dec. 13, 2006--AngioDynamics, Inc. (NASDAQ:ANGO) today announced that the company will release fiscal 2007 second quarter results after the market closes on Wednesday, January 3, 2007.

Eamonn P. Hobbs, president and chief executive officer, and Joseph G. Gerardi, chief financial officer, will host an investment community conference call beginning at 4:30 p.m. Eastern time on January 3rd to discuss these results and to answer questions.

To participate in the live call by telephone, please dial (800) 435-1261 from the U.S., or for international callers, please dial (617) 614-4076. Please enter the passcode: 78547643.

Those interested in listening to the conference call live via the Internet may do so by visiting the Investor Relations section of AngioDynamics' web site at <http://investor.angiodynamics.com>. To listen to the live call, please go to the Web site 15 minutes prior to its start to register, download, and install the necessary audio software.

A replay will be available on the Web site. A telephone replay will be available from 6:30 p.m. Eastern time on January 3, 2007 through 11:59 p.m. Eastern time on January 5 by dialing (888) 286-8010 (domestic) or (617) 801-6888 (international) and entering the passcode: 68179267.

### About AngioDynamics

AngioDynamics, Inc. is a leading provider of innovative medical devices used by interventional radiologists, vascular surgeons and other physicians for the minimally invasive diagnosis and treatment of peripheral vascular disease. AngioDynamics, Inc. designs, develops, manufactures and markets a broad line of therapeutic and diagnostic devices that enable interventional physicians, such as interventional radiologists, vascular surgeons and others, to treat peripheral vascular diseases and other non-coronary diseases. The Company's diverse product line includes angiographic products and accessories, dialysis products, vascular access products, PTA products, drainage products, thrombolytic products and venous products. More information is available at [www.angiodynamics.com](http://www.angiodynamics.com).

The statements made in this document contain certain forward-looking statements that involve a number of risks and uncertainties. Words such as "expects," "intends," "anticipates," "plans," "believes," "seeks," "estimates," or variations of such words and similar expressions, are intended to identify such forward-looking statements. Investors are cautioned that actual events or results may differ from the Company's expectations. In addition to the matters described above, the ability of the Company to develop its products, future actions by the FDA or other regulatory agencies, results of pending or future clinical trials, overall economic conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, as well as the risk factors listed from time to time in the SEC filings of AngioDynamics, Inc., including but not limited to its Annual Report on Form 10-K for the year ended June 3, 2006, may affect the actual results achieved by the Company.

CONTACT: AngioDynamics, Inc.  
Joe Gerardi, 800-772-6446 x115  
[www.AngioDynamics.com](http://www.AngioDynamics.com)

or  
Investor Relations Contacts:  
Lippert/Heilshorn & Associates, Inc.  
Kim Sutton Golodetz, 212-838-3777  
[kgolodetz@lhai.com](mailto:kgolodetz@lhai.com)

or  
Bruce Voss, 310-691-7100

bvoss@lhai.com

SOURCE: AngioDynamics, Inc.